Welcome to our dedicated page for Zevra Therapeutics SEC filings (Ticker: ZVRA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Zevra Therapeutics filings document the regulatory record of a Nasdaq-listed, Delaware commercial-stage rare-disease therapeutics company. Recent Form 8-K reports furnish quarterly financial results and corporate updates, record leadership and principal financial officer changes, and disclose compensatory arrangements and inducement awards tied to executive appointments.
The filing record also includes definitive proxy materials covering board matters, executive compensation and shareholder voting items. Material-event filings describe the completed transfer of Zevra's SDX portfolio, including AZSTARYS and KP1077, under an asset purchase and settlement agreement, while Exchange Act disclosures identify the company's common stock on the Nasdaq Global Select Market.
Zevra Therapeutics director John B. Bode exercised stock options to acquire 78,400 shares of common stock. On March 24, 2026, he exercised two option grants covering 39,200 shares each at exercise prices of $4.97 and $4.89 per share.
Following these exercises, Bode directly owns 123,400 shares of Zevra Therapeutics common stock. The transactions were reported as derivative exercises rather than open-market purchases or sales, indicating a shift from options-based compensation into outright share ownership.
Zevra Therapeutics, Inc. reported that its CFO, Justin A. Renz, received a grant of stock options to purchase 300,000 shares of common stock. The options have an exercise price of $9.55 per share, equal to the closing market price on March 18, 2026, and expire ten years after the grant date.
The award was made under Zevra’s 2023 Employment Inducement Award Plan and vests in four equal annual installments beginning on the first anniversary of the grant, subject to continued service. All underlying shares will vest in full immediately before a change of control, and vesting will be accelerated by 12 months if the CFO is terminated without cause or resigns for good reason.
ZEVRA THERAPEUTICS, INC. filed an insider ownership report identifying Justin A. Renz as its CFO and reporting person. The data show no reported purchases, sales, acquisitions, dispositions, exercises, gifts, tax withholdings, or restructuring transactions, and no listed derivative positions or holdings in this filing.
R. LaDuane Clifton reported proposed dispositions of Common Stock under a Form 144, including sales disclosed for 02/03/2026 of 11,000 shares and for 01/30/2026 of 3,000 shares.
The filing lists multiple prior and scheduled issuances or vesting events (restricted stock vesting and previously exercised options) with amounts shown in the excerpt, including a 230,306 share entry for 03/10/2026 and larger vesting entries on 01/31/2025 and 12/31/2025. The filing shows addresses and broker/issuer information for the transactions.
Zevra Therapeutics has entered into an Asset Purchase and Settlement Agreement with Commave Therapeutics, under which Commave will buy Zevra’s SDX portfolio, including AZSTARYS® (KP415) and KP1077, for $50.0 million in cash. Commave will pay $25.0 million at signing, $20.0 million within ten business days of the effective date, and $5.0 million within three days after delivery of specified manufacturing and patent records.
The deal terminates the 2019 AZSTARYS License Agreement and settles Delaware Chancery Court litigation between the parties, with mutual releases and a dismissal with prejudice to be filed. Zevra also repaid in full approximately $63.0 million outstanding under its senior secured term loan, and states this has resulted in a strong, debt-free balance sheet and greater financial and strategic flexibility.
Zevra Therapeutics, Inc. (ZVRA) is a commercial-stage rare disease company focused on expanding access to treatments for underserved patient populations. The company’s lead product, MIPLYFFA (arimoclomol), became the first FDA‑approved therapy for Niemann‑Pick disease type C in September 2024 and is marketed in combination with miglustat in the United States. Zevra also runs a global expanded access program and has filed a Marketing Authorization Application in the European Union, now under EMA review.
Following approval, Zevra received and then sold a rare pediatric disease priority review voucher, generating $148.3 million of net proceeds that strengthen its balance sheet. The acquisition of Acer Therapeutics in 2023 added OLPRUVA for urea cycle disorders and the late‑stage celiprolol program for Vascular Ehlers‑Danlos syndrome, where a Phase 3 event‑driven trial (DiSCOVER) had 52 enrolled participants as of December 31, 2025. Zevra also earns royalties and potential milestones from the ADHD drug AZSTARYS and is advancing KP1077 for idiopathic hypersomnia and narcolepsy, supported by orphan designation and a Phase 2 trial that informed Phase 3 dosing plans.
Zevra Therapeutics reported a strong turnaround for 2025, with net revenue of $106.5 million, up from $23.6 million in 2024, driven mainly by $87.4 million in MIPLYFFA net revenue and higher expanded‑access and royalty income.
The company generated 2025 net income of $83.2 million, or $1.40 basic EPS, compared with a prior-year net loss of $105.5 million, helped by a $148.3 million gain on sale of a priority review voucher and despite a $58.7 million intangible asset impairment.
Q4 2025 net revenue reached $34.1 million and net income was $12.2 million. Cash, cash equivalents and securities totaled $238.9 million as of December 31, 2025, supporting continued investment in MIPLYFFA, OLPRUVA and the celiprolol VEDS program.
The company highlighted progress for MIPLYFFA in Niemann‑Pick type C, including growing U.S. uptake and an EMA marketing application under review, and ongoing enrollment in the Phase 3 DiSCOVER trial for celiprolol. Zevra also relocated its headquarters to Boston and appointed Justin Renz as Chief Financial Officer, with a $520,000 base salary and options to purchase 300,000 shares vesting over four years.
Zevra Therapeutics President and CEO Neil F. McFarlane reported equity award vesting and a planned share sale. On February 7, 2026, 37,500 restricted stock units vested, converting into the same number of common shares as part of an award that vests in three annual installments.
On February 9, 2026, McFarlane sold 14,625 shares of common stock at a weighted average price of $8.5597 per share under a pre-arranged Rule 10b5-1(c) trading plan adopted on March 21, 2025. Following these transactions, he directly holds 387,225 common shares and 75,000 restricted stock units.
Zevra Therapeutics SVP, Finance & Corp Controller Timothy J. Sangiovanni reported a planned stock sale. On 02/03/2026, he sold 3,000 shares of Zevra Therapeutics common stock in open-market transactions at a weighted average price of $9.1827 per share.
The trades were executed in multiple lots at prices ranging from $8.93 to $9.52, and were made under a pre-arranged Rule 10b5-1(c) trading plan adopted on 03/28/2025. After this sale, he directly beneficially owns 29,590 Zevra common shares.
Zevra Therapeutics’ Chief Commercial Officer Joshua Schafer reported a pre-planned stock sale. On 02/03/2026, he sold 10,500 shares of Zevra Therapeutics common stock at a weighted average price of $9.1905 per share under a Rule 10b5-1(c) trading plan adopted on 03/27/2025. After this sale, he beneficially owned 62,278 shares held directly.